▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #797 by analyst upside · 2026-09-28
COLL
Collegium Pharmaceutical, Inc.
Healthcare · Market Cap $698M · P/E 17.7x
ANALYST PRICE TARGET
+117.5%
implied upside to consensus target
Current Price $22.53
Consensus Target $49.0
Bull Target $60.0
Bear Target $43.0
Analysts Covering 8
ANALYST CONSENSUS - BUY
Strong Buy
2
Buy
5
Hold
1
Sell
0
52-Week Low $21.65
52-Week High $50.79
YTD Return -50.5%
FUNDAMENTALS
Market Cap $698M
P/E Ratio (TTM) 17.7x
Forward P/E 3.4x
EPS (TTM) $1.27
PEG Ratio 0.66
Dividend Yield N/A
Revenue (TTM) $808M
Profit Margin 5.9%
52-WEEK RANGE
52-Week Low $21.65
52-Week High $50.79
Current Price $22.53
Bear Target $43.0
Bull Target $60.0
● Now $22.53 ● Target $49.0
TRADING DATA
Avg Volume 708K
YTD Return -50.5%
Analyst Count 8
Consensus Buy
Upside to Target +117.5%
Last Updated 2026-09-28

ANALYST SUMMARY

Collegium Pharmaceutical, Inc. (COLL) is currently trading at $22.53 with a Wall Street consensus price target of $49.0, implying potential upside of 117.5% over the next 12 months. 8 analysts currently cover COLL, with a consensus rating of Buy - 88% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $60.0, while the most cautious has a target of $43.0.

COLL operates in the Healthcare sector with a market capitalisation of $698M. The stock is down 50.5% year-to-date and is currently trading near the lower end of its 52-week range of $21.65 – $50.79.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for COLL, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Oppenheimer ● Initiated
Outperform 2026-09-23 14% win rate (7 calls)
Truist Securities - Reiterated
Buy → Buy 2026-09-09 Building track record
Leerink Partners ● Initiated
Outperform 2026-09-09 29% win rate (7 calls)
Barclays - Reiterated
Overweight → Overweight 2026-08-19 Building track record
Piper Sandler reit
Neutral → Neutral 2026-08-07 14% win rate (7 calls)
Needham - Reiterated
Buy → Buy 2026-08-06 20% win rate (5 calls)
HC Wainwright & Co. reit
Buy → Buy 2026-03-20 31% win rate (48 calls)
Needham reit
Buy → Buy 2026-03-19 20% win rate (5 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
54
out of 100
Coverage depth
17/30
Consensus clarity
15/30
Vote unanimity
20/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →